Streetbeat News

Products Services

RANI

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research. The presentation will detail the daily administration of an oral robotic pill (RT-102) that safely and reliably delivers Teriparatide with high bioavailability in women volunteers, based on a Phase I study.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:35 pm

SXTP

60 Degrees Pharmaceuticals has suspended its Phase IIB study of tafenoquine for COVID-19, following FDA advice that the study may not be feasible in the U.S. The company will now focus on commercializing treatments for malaria and tick-borne diseases, including a Phase IIA study of tafenoquine in hospitalized babesiosis patients. A pre-IND meeting request with the FDA for babesiosis is planned for Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:18 pm

RLAY

Relay Therapeutics announced initial clinical data for RLY-4008 in patients with FGFR2-altered solid tumors, which led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:17 pm

VIGL

Vigil Neuroscience, Inc. has received a response from the FDA regarding the partial clinical hold on its drug VG-3927. The FDA has requested additional non-clinical data to exceed the maximum exposure limit in the Phase 1 trial. The company is working on obtaining the required data and will work with the FDA to address the hold. The company's statements about its TREM2 agonist program remain unchanged.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:15 pm

RLAY

Relay Therapeutics has reported initial clinical data for RLY-4008 (Lirafugratinib) in patients with FGFR2-altered solid tumors. The data shows activity across several sub-groups, including patients with FGFR2-fusion tumors and FGFR2-altered HR+/HER2- breast cancer. The company also announced that updates to its pipeline have extended its cash runway by one year into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:10 pm

SLS

SELLAS Life Sciences has provided an update on its Phase 3 REGAL clinical trial for Galinpepimut-S in Acute Myeloid Leukemia. The company expects to complete enrollment ex-China in November 2023 and commence enrollment in China this quarter.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:06 pm

TTOO

T2 Biosystems has submitted an FDA 510(K) application to expand the pathogen detection on its FDA-cleared T2Bacteria Panel to include detection of Acinetobacter Baumannii.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:04 pm

HCP

Piper Sandler analyst James E. Fish has reiterated a Neutral rating on HashiCorp, Inc. (NASDAQ:HCP) with a price target of $30. The analyst praised the company's go-to-market simplification and potential for new bundles. Fish is also optimistic about the release of features and add-ons that could drive differentiation against open-source offerings. Despite the positive outlook, Fish remains Neutral as the strategic moves will take time to reflect in the fundamentals.

Portfolio Pulse from Nabaparna Bhattacharya

October 12, 2023 | 7:47 pm

TBLT

ToughBuilt Industries has been granted European Patent Number EP3782502 titled 'Storage Bag With Enhanced Interior Visibility'. This patent could potentially increase the company's market share in Europe.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 7:41 pm

SONY

Sony Group Corp. has announced its October 2023 lineup for PlayStation Plus Games Catalog, featuring a total of 15 games. Notable additions include Gotham Knights, Disco Elysium: The Final Cut, and other Halloween-themed titles. 11 games will be available to Extra and Premium members, with four exclusively for Premium members.

Portfolio Pulse from Franca Quarneti

October 12, 2023 | 7:15 pm